Recombinant grass pollen vaccine - Biomay

Drug Profile

Recombinant grass pollen vaccine - Biomay

Alternative Names: BM-32; CS-BM32-001

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomay
  • Class Allergens; Antiallergics; Plant allergy immunotherapies; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Allergic rhinitis; Hypersensitivity

Most Recent Events

  • 26 Jan 2017 Adverse events and efficacy data from a phase IIb trial in Hypersensitivity released by Biomay AG
  • 01 Jan 2017 Biomay completes a phase II trial in Hypersensitivity in Austria (SC) (NCT02643641)
  • 10 Nov 2016 Recombinant grass pollen vaccine - Biomay AG is available for licensing as of 10 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top